Stockscreener 앱 받기
3.21
0.31%
0.010
시장 영업 전:
3.17
-0.04
-1.25%
Newcelx Ltd 주식(NCEL)의 최신 뉴스
NewcelX Stem Cell Platform Strengthened by Peer-Reviewed AstroRx Study in Multiple Sclerosis - TipRanks
Peer-reviewed AstroRx data underscore NewcelX (NCEL) stem cell platform - Stock Titan
Exclusive: NewcelX eyes accelerated 2026 execution for diabetes drug - MSN
NewcelX Calls June 30, 2026 Shareholders’ Meeting as 2025 Losses Deepen - TipRanks
NewcelX Stock Moves Up Ahead of FDA Meeting on Diabetes Treatment - Bez Kabli
Exclusive: NewcelX advances diabetes therapy toward human trials with FDA pre-IND submission - MSN
NCEL Should I Buy - Intellectia AI
NewcelX Ltd. (NCEL) Gains Ground: Testing Key Resistance LevelsStatistical Arbitrage - newsline.com
Newcelx submits pre-IND package for NCEL-101 to FDA - BioWorld News
NewcelX Files Pre-IND With FDA for NCEL-101 Type 1 Diabetes Cell Therapy - TipRanks
Newcelx submits pre-IND package to FDA for NCEL-101 for treatment of type 1 diabetes - marketscreener.com
NewcelX (Nasdaq: NCEL) files FDA pre-IND for NCEL-101 diabetes cell therapy - Stock Titan
NewcelX Ltd. Schedules Pre-IND Meeting with FDA to Propel Type 1 Diabetes Treatment NCEL-101 into First-In-Human Trials - Quiver Quantitative
Stem cell therapy targeting a potential type 1 diabetes cure nears trials - Stock Titan
NCEL Stock Price, Quote & Chart | NEWCELX LTD (NASDAQ:NCEL) - ChartMill
[EFFECT] NewcelX Ltd. SEC Filing - Stock Titan
TradingKey - TradingKey
NewcelX (NASDAQ: NCEL) registers 2.26M shares for resale by investors - Stock Titan
Why NewcelX (NCEL) is still under the radar (Risk Aversion) 2026-05-06Top Analyst Buy Signals - Newser
NLS Pharmaceutics and Kadimastem Announce Completion of Material Conditions Precedent for Merger Transaction and Delisting Date of Kadimastem's Shares - Quantisnow
NewcelX Ltd. (NCEL) updates resale prospectus for up to 500,000 shares - Stock Titan
How NewcelX (NCEL) differentiates itself from competitors (Investor Concern) 2026-05-05High Interest Stocks - newser.com
Julien Ruggieri Discloses Investment at NewcelX Ltd. with 25.3% Stake - TradingView
League Jinn holds 25.3% ownership stake in NewcelX (NCEL) - Stock Titan
EXCLUSIVE: NewcelX Eyes Accelerated 2026 Execution For Diabetes Drug - Yahoo Finance
NLSPW SEC FilingsNEWCELX LTD 10-K, 10-Q, 8-K Forms - Stock Titan
Olivier Samuel Buys Handful Of Shares In NewcelX - 富途牛牛
Despite NewcelX's Pullback, Insiders Still Gained ₪136k - Yahoo Finance
NewcelX Loses US$2.3m Market Value But Insiders See Windfall Of ₪136k - simplywall.st
NCEL | NewcelX Ltd. Ordinary Shares Insider Trading - Quiver Quantitative
NewcelX Ltd. announced that it has received $1.349994 million in funding - marketscreener.com
NCEL - Finviz
NewcelX Posts 2025 Results and Bolsters Funding to Accelerate Type 1 Diabetes Program - TipRanks
Newcelx Reports Financial Results for 2025 an - Moomoo
NewcelX Reports Financial Results for 2025 and Provides Shareholders with Update on Accelerated Development of Type 1 Diabetes Treatment in Collaboration with Eledon Pharmaceuticals in 2026 - The Manila Times
NewcelX and Eledon Pharmaceuticals Collaborate on NCEL-101 for Type 1 Diabetes, Reporting Strong Financial Position and Strategic Growth Plans - Quiver Quantitative
NewcelX makes Type 1 diabetes program its 2026 flagship - Stock Titan
Insider Buying: Olivier Samuel Acquires 81,818 Shares of NewcelX Ltd (NCEL) - GuruFocus
NewcelX Ltd. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
NewcelX (NCEL) 20-F: Kadimastem merger, heavy losses and funding risk - Stock Titan
NewcelX Ltd. (NCEL) director buys shares and long-dated warrants - Stock Titan
NewcelX Ltd. (NCEL) Stock Price Today - MEXC Exchange
NewcelX (NCEL) Trend Analysis | Q1 2025: Earnings ReportDividend Report - Cổng thông tin điện tử tỉnh Lào Cai
NewcelX updates presentation on diabetes therapy collaboration By Investing.com - Investing.com India
Newcelx updates corporate presentation to highlight type 1 diabetes flagship program - marketscreener.com
NewcelX Highlights Type 1 Diabetes Flagship and Eledon Collaboration in Updated April 2026 Presentation - TipRanks
1.27%
1.43%
자본화:
|
볼륨(24시간):